Valuation : Modalis Therapeutics Corporation

Market Cap 3.65B 23.41M 20.14M 18.95M 17.31M 32.39M 2.21B 32.47M 224M 86.9M 1.13B 87.9M 85.98M P/E 2024
-3.57x
P/E 2025 -2.01x
Enterprise Value 841M 5.39M 4.64M 4.36M 3.99M 7.46M 509M 7.48M 51.56M 20.01M 261M 20.24M 19.8M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
92.85%
Yield 2024 *
-
Yield 2025 -
08-10 Modalis Therapeutics Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 CI
06-12 Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC CI
05-27 Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC CI
05-13 Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-12 Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25/08/25 Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC CI
07/08/25 Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC CI
07/07/25 Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment MT
16/06/25 Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan MT
09/06/25 SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy CI
01/05/25 Modalis Issues 21,900 Shares for Restricted Stock Remuneration MT
27/01/25 Modalis Therapeutics Secures Japanese Patent for Gene Therapy MT
06/01/25 JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease MT
1 week+6.06%
Current month+2.94%
1 month+9.38%
3 months-10.26%
6 months-37.50%
Current year-37.50%
1 week 33
Extreme 33
36
1 month 31
Extreme 31
36
Current year 29
Extreme 29
83
1 year 29
Extreme 29
92
3 years 29
Extreme 29
203
5 years 29
Extreme 29
1,667
10 years 29
Extreme 29
4,070
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2016
Director of Finance/CFO 63 -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/01/2016
Director/Board Member 60 01/01/2016
Director/Board Member 68 01/01/2016
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/24 Others

Founder

10,000 0.0220%
24/09/24 Others

Founder

10,000 0.0220%
24/09/24 Others

Founder

6,000 0.0132%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+6.06%-60.67%-78.53% 23.41M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.24%+0.84%+32.36%+151.97% 27.91B
Weighted average by Cap. -1.52%+0.18%+38.37%+137.33%

Financials

2024 2025
Net sales - -
Net income -1.32B -8.44M -7.26M -6.83M -6.24M -11.68M -797M -11.71M -80.74M -31.33M -409M -31.69M -31M -2.15B -13.79M -11.87M -11.16M -10.2M -19.08M -1.3B -19.13M -132M -51.19M -668M -51.78M -50.65M
Net Debt -3.58B -22.91M -19.71M -18.55M -16.94M -31.69M -2.16B -31.78M -219M -85.04M -1.11B -86.02M -84.15M -2.81B -18.02M -15.51M -14.59M -13.33M -24.93M -1.7B -25M -172M -66.89M -873M -67.66M -66.19M
Logo Modalis Therapeutics Corporation
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Employees
-
Date Price Change Volume
04/09/26 ¥35.00 0.00% 159,300
03/09/26 ¥35.00 +2.94% 89,500
02/09/26 ¥34.00 -2.86% 541,500
01/09/26 ¥35.00 +2.94% 565,900
31/08/26 ¥34.00 +3.03% 1,162,100

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4883 Stock